FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:133-144 July 14, 2005 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Doroshow, J. H. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations.

Methods EGFR expression was evaluated immunohistochemically in non–small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the number of EGFR genes.

Results In univariate analyses, survival was longer in the erlotinib group than in the placebo group when EGFR was expressed (hazard ratio for death, 0.68; P=0.02) or there was a high number of copies of EGFR (hazard ratio, 0.44; P=0.008). In multivariate analyses, adenocarcinoma (P=0.01), never having smoked (P<0.001), and expression of EGFR (P=0.03) were associated with an objective response. In multivariate analysis, survival after treatment with erlotinib was not influenced by the status of EGFR expression, the number of EGFR copies, or EGFR mutation.

Conclusions Among patients with non–small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

Source Information

From the University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Toronto (M.-S.T., A.S., J.-C.C., C.-Q.Z., S.K.-R., J.S., T.Z., N.L., P.M., G.C.S., F.A.S.); the Ottawa Health Research Institute, University of Ottawa, Ottawa (I.L., M.D., A.L.); OSI Pharmaceuticals, Boulder, Colo. (F.R.); and the National Cancer Institute of Canada Clinical Trials Group and Queen's University, Kingston, Ont., Canada (L.S., M.W., K.D., J.P.).

Drs. Sakurada, Cutz, and Zhu contributed equally to this article.

Full Text of this Article

Related Letters:

Erlotinib in Lung Cancer
Nabhan C., Bitran J. D., Takano T., Ohe Y., Pao W., Ladanyi M., Miller V. A., the Lung Cancer Oncogenome Group , Shepherd F. A., Seymour L., Tsao M.-S., Kamel-Reid S., Shepherd F. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1739-1741, Oct 20, 2005. Correspondence

Assessing EGFR Mutations
Marchetti A., Felicioni L., Buttitta F., Tsao M.-S., Kamel-Reid S., Shepherd F. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:526-528, Feb 2, 2006. Correspondence

This article has been cited by other articles:

• Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C., Gutman, S. I. (2009). A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI J Natl Cancer Inst 101: 1453-1463 [Abstract] [Full Text]  
• Peled, N., Yoshida, K., Wynes, M. W., Hirsch, F. R. (2009). Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 137-144 [Abstract]  
• Varella-Garcia, M, Diebold, J, Eberhard, D A, Geenen, K, Hirschmann, A, Kockx, M, Nagelmeier, I, Ruschoff, J, Schmitt, M, Arbogast, S, Cappuzzo, F (2009). EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 62: 970-977 [Abstract] [Full Text]  
• Rho, J. K., Choi, Y. J., Lee, J. K., Ryoo, B.-Y., Na, I. I., Yang, S. H., Lee, S. S., Kim, C. H., Yoo, Y. D., Lee, J. C. (2009). The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Mol Cancer Res 7: 1736-1743 [Abstract] [Full Text]  
• Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E. J., Rodig, S. J., Chirieac, L. R., Kwak, E. L., Lynch, T. J., Iafrate, A. J. (2009). Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. JCO 27: 4247-4253 [Abstract] [Full Text]  
• William, W. N. Jr, Gold, K. A., Kim, E. S. (2009). Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 20: 1455-1457 [Full Text]  
• Jackman, D. M., Miller, V. A., Cioffredi, L.-A., Yeap, B. Y., Janne, P. A., Riely, G. J., Ruiz, M. G., Giaccone, G., Sequist, L. V., Johnson, B. E. (2009). Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clin. Cancer Res. 15: 5267-5273 [Abstract] [Full Text]  
• Ocak, S., Sos, M. L., Thomas, R. K., Massion, P. P. (2009). High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J 34: 489-506 [Abstract] [Full Text]  
• Chang, E. T., Shema, S. J., Wakelee, H. A., Clarke, C. A., Gomez, S. L. (2009). Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. Cancer Epidemiol. Biomarkers Prev. 18: 2248-2255 [Abstract] [Full Text]  
• Sun, M., Behrens, C., Feng, L., Ozburn, N., Tang, X., Yin, G., Komaki, R., Varella-Garcia, M., Hong, W. K., Aldape, K. D., Wistuba, I. I. (2009). HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. Clin. Cancer Res. 15: 4829-4837 [Abstract] [Full Text]  
• GARASSINO, M. C., BORGONOVO, K., ROSSI, A., MANCUSO, A., MARTELLI, O., TINAZZI, A., DI COSIMO, S., LA VERDE, N., SBURLATI, P., BIANCHI, C., FARINA, G., TORRI, V. (2009). Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis. Anticancer Res 29: 2691-2701 [Abstract] [Full Text]  
• Tassinari, D., Scarpi, E., Sartori, S., Tamburini, E., Santelmo, C., Tombesi, P., Lazzari-Agli, L. (2009). Second-Line Treatments in Non-small Cell Lung Cancer: A Systematic Review of Literature and Metaanalysis of Randomized Clinical Trials. Chest 135: 1596-1609 [Abstract] [Full Text]  
• RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]  
• Freeman, D. J., Bush, T., Ogbagabriel, S., Belmontes, B., Juan, T., Plewa, C., Van, G., Johnson, C., Radinsky, R. (2009). Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Molecular Cancer Therapeutics 8: 1536-1546 [Abstract] [Full Text]  
• Rickman, O. B., Vohra, P. K., Sanyal, B., Vrana, J. A., Aubry, M.-C., Wigle, D. A., Thomas, C. F. Jr. (2009). Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors. Clin. Cancer Res. 15: 3315-3324 [Abstract] [Full Text]  
• Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella-Garcia, M., Duffield, E., Ataman, O. U., Zarenda, M., Armour, A. A. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. JCO 27: 2253-2260 [Abstract] [Full Text]  
• Ludovini, V., Bellezza, G., Pistola, L., Bianconi, F., Di Carlo, L., Sidoni, A., Semeraro, A., Del Sordo, R., Tofanetti, F. R., Mameli, M. G., Daddi, G., Cavaliere, A., Tonato, M., Crino, L. (2009). High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20: 842-849 [Abstract] [Full Text]  
• Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., del Grammastro, M., Sciarrotta, M. G., Buttitta, F., Incarbone, M., Toschi, L., Finocchiaro, G., Destro, A., Terracciano, L., Roncalli, M., Alloisio, M., Santoro, A., Varella-Garcia, M. (2009). Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients. JCO 27: 1667-1674 [Abstract] [Full Text]  
• Witta, S. E., Dziadziuszko, R., Yoshida, K., Hedman, K., Varella-Garcia, M., Bunn, P. A. Jr, Hirsch, F. R. (2009). ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 20: 689-695 [Abstract] [Full Text]  
• Martin, V, Mazzucchelli, L, Frattini, M (2009). An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J. Clin. Pathol. 62: 314-324 [Abstract] [Full Text]  
• Hughes, A. N., O'Brien, M. E.R., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., Price, A. (2009). Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers. JCO 27: 1220-1226 [Abstract] [Full Text]  
• Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., Shepherd, F. A. (2009). The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. The Oncologist 14: 253-263 [Abstract] [Full Text]  
• Cappuzzo, F., Janne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., Varella-Garcia, M. (2009). MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20: 298-304 [Abstract] [Full Text]  
• Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P. L., Biasco, G. (2009). Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 20: 213-226 [Abstract] [Full Text]  
• Okabe, T., Okamoto, I., Tsukioka, S., Uchida, J., Hatashita, E., Yamada, Y., Yoshida, T., Nishio, K., Fukuoka, M., Janne, P. A., Nakagawa, K. (2009). Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non-small cell Lung Cancer Cell Lines with MET Amplification. Clin. Cancer Res. 15: 907-913 [Abstract] [Full Text]  
• Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P. A. Jr, Varella-Garcia, M., Gandara, D. R. (2009). In Reply. JCO 27: 465-467 [Full Text]  
• Kancha, R. K., von Bubnoff, N., Peschel, C., Duyster, J. (2009). Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy. Clin. Cancer Res. 15: 460-467 [Abstract] [Full Text]  
• Socinski, M. A. (2009). What Guides Decisions about the Use of Epidermal Growth Factor Receptor Antibody or Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer?. Am Soc Clin Oncol Ed Book 2009: 436-443 [Abstract] [Full Text]  
• Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., Tamura, T. (2008). EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan. JCO 26: 5589-5595 [Abstract] [Full Text]  
• Berhoune, M., Banu, E., Scotte, F., Prognon, P., Oudard, S., Bonan, B. (2008). Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer. The Annals of Pharmacotherapy 42: 1640-1652 [Abstract] [Full Text]  
• Herbst, R. S., Sandler, A. (2008). Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. The Oncologist 13: 1166-1176 [Abstract] [Full Text]  
• Kelly, K., Redman, M. W., Gandara, D. R. (2008). In Reply. JCO 26: 4850-4851 [Full Text]  
• Simon, R. (2008). The Use of Genomics in Clinical Trial Design. Clin. Cancer Res. 14: 5984-5993 [Abstract] [Full Text]  
• Hirsch, F. R., Varella-Garcia, M., Dziadziuszko, R., Xiao, Y., Gajapathy, S., Skokan, M., Lin, M., O'Neill, V., Bunn, P. A. Jr. (2008). Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 6317-6323 [Abstract] [Full Text]  
• Herbst, R. S., Heymach, J. V., Lippman, S. M. (2008). Lung Cancer. NEJM 359: 1367-1380 [Full Text]  
• Horlings, H. M., van Laar, R. K., Kerst, J.-M., Helgason, H. H., Wesseling, J., van der Hoeven, J. J.M., Warmoes, M. O., Floore, A., Witteveen, A., Lahti-Domenici, J., Glas, A. M., Van't Veer, L. J., de Jong, D. (2008). Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary. JCO 26: 4435-4441 [Abstract] [Full Text]  
• Crino, L., Cappuzzo, F., Zatloukal, P., Reck, M., Pesek, M., Thompson, J. C., Ford, H. E.R., Hirsch, F. R., Varella-Garcia, M., Ghiorghiu, S., Duffield, E. L., Armour, A. A., Speake, G., Cullen, M. (2008). Gefitinib Versus Vinorelbine in Chemotherapy-Naive Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. JCO 26: 4253-4260 [Abstract] [Full Text]  
• Oza, A. M., Eisenhauer, E. A., Elit, L., Cutz, J.-C., Sakurada, A., Tsao, M. S., Hoskins, P. J., Biagi, J., Ghatage, P., Mazurka, J., Provencher, D., Dore, N., Dancey, J., Fyles, A. (2008). Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. JCO 26: 4319-4325 [Abstract] [Full Text]  
• Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., Kamel-Reid, S., Seymour, L., Shepherd, F. A., Tsao, M.-S. (2008). Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. JCO 26: 4268-4275 [Abstract] [Full Text]  
• Stinchcombe, T. E., Socinski, M. A. (2008). Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. The Oncologist 13: 933-944 [Abstract] [Full Text]  
• Gazdar, A. F., Minna, J. D. (2008). Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Cancer Prevention Research 1: 156-160 [Full Text]  
• Tang, X., Varella-Garcia, M., Xavier, A. C., Massarelli, E., Ozburn, N., Moran, C., Wistuba, I. I. (2008). Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Cancer Prevention Research 1: 192-200 [Abstract] [Full Text]  
• Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., Yang, P.-C. (2008). Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clin. Cancer Res. 14: 4877-4882 [Abstract] [Full Text]  
• Pino, M. S., Balsamo, M., Di Modugno, F., Mottolese, M., Alessio, M., Melucci, E., Milella, M., McConkey, D. J., Philippar, U., Gertler, F. B., Natali, P. G., Nistico, P. (2008). Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clin. Cancer Res. 14: 4943-4950 [Abstract] [Full Text]  
• Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., Haber, D. A. (2008). Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. NEJM 359: 366-377 [Abstract] [Full Text]  
• Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P. A. Jr, Varella-Garcia, M., Gandara, D. R. (2008). Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. JCO 26: 3351-3357 [Abstract] [Full Text]  
• Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., Lee, J., Richards, W. G., Sugarbaker, D. J., Ducko, C., Lindeman, N., Marcoux, J. P., Engelman, J. A., Gray, N. S., Lee, C., Meyerson, M., Janne, P. A. (2008). EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. Clin. Cancer Res. 14: 4275-4283 [Abstract] [Full Text]  
• Ahn, M.-J., Park, B.-B., Ahn, J. S., Kim, S. W., Kim, H.-T., Lee, J. S., Kang, J. H., Cho, J. Y., Song, H. S., Park, S. H., Sohn, C. H., Shin, S. W., Choi, J. H., Ki, C.-S., Park, C. K., Holmes, A. J., Janne, P. A., Park, K. (2008). Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?. Clin. Cancer Res. 14: 3860-3866 [Abstract] [Full Text]  
• Felip, E., Rojo, F., Reck, M., Heller, A., Klughammer, B., Sala, G., Cedres, S., Peralta, S., Maacke, H., Foernzler, D., Parera, M., Mocks, J., Saura, C., Gatzemeier, U., Baselga, J. (2008). A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Clin. Cancer Res. 14: 3867-3874 [Abstract] [Full Text]  
• Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., Huang, C.-L., Bean, J., Cheng, A.-L., Pao, W., Yang, P.-C. (2008). Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non-Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. JCO 26: 2745-2753 [Abstract] [Full Text]  
• John, T., Caballero, O. L., Svobodova, S. J., Kong, A., Chua, R., Browning, J., Fortunato, S., Deb, S., Hsu, M., Gedye, C. A., Davis, I. D., Altorki, N., Simpson, A. J., Chen, Y.-T., Monk, M., Cebon, J. S. (2008). ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 3291-3298 [Abstract] [Full Text]  
• Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H.M., Crowley, J. J., Gandara, D. R. (2008). Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023. JCO 26: 2450-2456 [Abstract] [Full Text]  
• Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., Lynch, T. J. (2008). First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. JCO 26: 2442-2449 [Abstract] [Full Text]  
• Shepherd, F. A. (2008). Molecular Selection of Patients for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Inhibitors: Not Quite Ready for Prime Time. JCO 26: 2426-2427 [Full Text]  
• Engelman, J. A., Janne, P. A. (2008). Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2895-2899 [Abstract] [Full Text]  
• Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., Shepherd, F. A. (2008). Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. JCO 26: 2350-2357 [Abstract] [Full Text]  
• Hodkinson, P. S., MacKinnon, A., Sethi, T. (2008). Targeting Growth Factors in Lung Cancer. Chest 133: 1209-1216 [Abstract] [Full Text]  
• Sleijfer, S., Wiemer, E. (2008). Editorial: The Long and Winding Road to Better Cancer Cell-Specific Therapies. The Oncologist 13: 593-595 [Full Text]  
• Wang, Y.-C., Kulp, S. K., Wang, D., Yang, C.-C., Sargeant, A. M., Hung, J.-H., Kashida, Y., Yamaguchi, M., Chang, G.-D., Chen, C.-S. (2008). Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors. Cancer Res. 68: 2820-2830 [Abstract] [Full Text]  
• Seiwert, T. Y., Haraf, D. J., Cohen, E. E.W., Stenson, K., Witt, M. E., Dekker, A., Kocherginsky, M., Weichselbaum, R. R., Chen, H. X., Vokes, E. E. (2008). Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer. JCO 26: 1732-1741 [Abstract] [Full Text]  
• Kumar, A., Petri, E. T., Halmos, B., Boggon, T. J. (2008). Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. JCO 26: 1742-1751 [Abstract] [Full Text]  
• Yatabe, Y., Takahashi, T., Mitsudomi, T. (2008). Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. Cancer Res. 68: 2106-2111 [Abstract] [Full Text]  
• D'Addario, G., Rauch, D., Stupp, R., Pless, M., Stahel, R., Mach, N., Jost, L., Widmer, L., Tapia, C., Bihl, M., Mayer, M., Ribi, K., Lerch, S., Bubendorf, L., Betticher, D. C. (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19: 739-745 [Abstract] [Full Text]  
• Na, I. I., Byun, B. H., Kang, H. J., Cheon, G. J., Koh, J. S., Kim, C. H., Choe, D. H., Ryoo, B.-Y., Lee, J. C., Lim, S. M., Yang, S. H. (2008). 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 2036-2041 [Abstract] [Full Text]  
• Tawbi, H., Thomas, D., Lucas, D. R., Biermann, J. S., Schuetze, S. M., Hart, A. L., Chugh, R., Baker, L. H. (2008). Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors. The Oncologist 13: 459-466 [Abstract] [Full Text]  
• Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A., Herbst, R. S., Heller, G., Ladanyi, M., Pao, W., Johnson, D. H. (2008). Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. JCO 26: 1472-1478 [Abstract] [Full Text]  
• Ciardiello, F., Tortora, G. (2008). EGFR Antagonists in Cancer Treatment. NEJM 358: 1160-1174 [Full Text]  
• Rudin, C. M., Liu, W., Desai, A., Karrison, T., Jiang, X., Janisch, L., Das, S., Ramirez, J., Poonkuzhali, B., Schuetz, E., Fackenthal, D. L., Chen, P., Armstrong, D. K., Brahmer, J. R., Fleming, G. F., Vokes, E. E., Carducci, M. A., Ratain, M. J. (2008). Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. JCO 26: 1119-1127 [Abstract] [Full Text]  
• Rocconi, R. P., Kirby, T. O., Seitz, R. S., Beck, R., Straughn, J. M. Jr, Alvarez, R. D., Huh, W. K. (2008). Lipoxygenase Pathway Receptor Expression in Ovarian Cancer. Reproductive Sciences 15: 321-326 [Abstract]  
• Okabe, T., Okamoto, I., Tsukioka, S., Uchida, J., Iwasa, T., Yoshida, T., Hatashita, E., Yamada, Y., Satoh, T., Tamura, K., Fukuoka, M., Nakagawa, K. (2008). Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Molecular Cancer Therapeutics 7: 599-606 [Abstract] [Full Text]  
• Pinter, F., Papay, J., Almasi, A., Sapi, Z., Szabo, E., Kanya, M., Tamasi, A., Jori, B., Varkondi, E., Moldvay, J., Szondy, K., Keri, G., Dominici, M., Conte, P., Eckhardt, S., Kopper, L., Schwab, R., Petak, I. (2008). Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. J. Mol. Diagn. 10: 160-168 [Abstract] [Full Text]  
• Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., Bar-Eli, M., McConkey, D. J., Dinney, C. P.N. (2008). Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. Clin. Cancer Res. 14: 1478-1486 [Abstract] [Full Text]  
• Burris, H. III, Rocha-Lima, C. (2008). New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. The Oncologist 13: 289-298 [Abstract] [Full Text]  
• Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J.-L., Lowenberg, B., Stone, R. M., De Porre, P., Wang, Y., Karp, J. E. (2008). A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111: 2589-2596 [Abstract] [Full Text]  
• Lilenbaum, R., Axelrod, R., Thomas, S., Dowlati, A., Seigel, L., Albert, D., Witt, K., Botkin, D. (2008). Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2. JCO 26: 863-869 [Abstract] [Full Text]  
• Eberhard, D. A., Giaccone, G., Johnson, B. E. (2008). Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. JCO 26: 983-994 [Abstract] [Full Text]  
• Garcia, A. A. (2008). Small Molecules: Big Changes in the Cancer Treatment Paradigm. Journal of Pharmacy Practice 21: 17-35 [Abstract]  
• Bradbury, P. A., Heist, R. S., Kulke, M. H., Zhou, W., Marshall, A. L., Miller, D. P., Su, L., Park, S., Temel, J., Fidias, P., Sequist, L., Lynch, T. J., Wain, J. C., Shepherd, F. A., Christiani, D. C., Liu, G. (2008). A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies. Cancer Epidemiol. Biomarkers Prev. 17: 204-211 [Abstract] [Full Text]  
• Duffy, A., Kortmansky, J., Schwartz, G. K., Capanu, M., Puleio, S., Minsky, B., Saltz, L., Kelsen, D. P., O'Reilly, E. M. (2008). A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19: 86-91 [Abstract] [Full Text]  
• de Marinis, F., Grossi, F. (2008). Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. The Oncologist 13: 14-20 [Abstract] [Full Text]  
• Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D., Alam, Y., Kreisman, H., Graze, P., Maher, J., Ross, H. J., Ellis, P. M., McNulty, W., Kaplan, E., Pautret, V., Weber, M. R., Shepherd, F. A. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer. JCO 25: 5777-5784 [Abstract] [Full Text]  
• Solit, D. B., Santos, E., Pratilas, C. A., Lobo, J., Moroz, M., Cai, S., Blasberg, R., Sebolt-Leopold, J., Larson, S., Rosen, N. (2007). 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Res. 67: 11463-11469 [Abstract] [Full Text]  
• Holdsworth, C. H., Badawi, R. D., Manola, J. B., Kijewski, M. F., Israel, D. A., Demetri, G. D., Van den Abbeele, A. D. (2007). CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor. Am. J. Roentgenol. 189: W324-W330 [Abstract] [Full Text]  
• Thomas, F., Rochaix, P., Benlyazid, A., Sarini, J., Rives, M., Lefebvre, J. L., Allal, B. C., Courbon, F., Chatelut, E., Delord, J.-P. (2007). Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 13: 7086-7092 [Abstract] [Full Text]  
• Liu, W., Wu, X., Zhang, W., Montenegro, R. C., Fackenthal, D. L., Spitz, J. A., Huff, L. M., Innocenti, F., Das, S., Cook,, E. H. Jr., Cox, N. J., Bates, S. E., Ratain, M. J. (2007). Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines. Clin. Cancer Res. 13: 6788-6795 [Abstract] [Full Text]  
• Wu, W., O'Reilly, M. S., Langley, R. R., Tsan, R. Z., Baker, C. H., Bekele, N., Tang, X. M., Onn, A., Fidler, I. J., Herbst, R. S. (2007). Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Molecular Cancer Therapeutics 6: 2652-2663 [Abstract] [Full Text]  
• Janne, P. A., von Pawel, J., Cohen, R. B., Crino, L., Butts, C. A., Olson, S. S., Eiseman, I. A., Chiappori, A. A., Yeap, B. Y., Lenehan, P. F., Dasse, K., Sheeran, M., Bonomi, P. D. (2007). Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer. JCO 25: 3936-3944 [Abstract] [Full Text]  
• Arenberg, D. (2007). Bronchioloalveolar Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 306S-313S [Abstract] [Full Text]  
• Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., Tanimoto, M. (2007). Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non Small Cell Lung Cancer Cell Line. Cancer Res. 67: 7807-7814 [Abstract] [Full Text]  
• Godin-Heymann, N., Bryant, I., Rivera, M. N., Ulkus, L., Bell, D. W., Riese, D. J. II, Settleman, J., Haber, D. A. (2007). Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. Cancer Res. 67: 7319-7326 [Abstract] [Full Text]